Physician profile
Cetessa Mack
NPI 1124423777
$850.48
in general payments reported to CMS, 2019-2025
10 companies · $14.67 in 2025
The $14.67 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $274 · 2023: $133 · 2024: $31.57 · 2025: $14.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $179.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $217.84 | 2021 | |
| Collegium Pharmaceutical, INC. | $209.75 | 2021-2023 | Belbuca |
| Scilex Pharmaceuticals INC. | $186.16 | 2021-2024 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.79 | 2021-2024 | Relistor |
| Tersera Therapeutics LLC | $56.80 | 2022 | |
| Nalu Medical, INC. | $22.64 | 2023 | Nalu Neurostimulation System |
| Pfizer INC. | $15.82 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $14.67 | 2025 | |
| Grt US Holding, INC. | $14.46 | 2022 | |
| Medtronic, INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cetessa Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.